Search results for "From ACP Journal Club"
In type 1 diabetes, adding liraglutide to insulin increased hypoglycemia and hyperglycemia with ketosis
The study authors concluded that the negative effects observed would limit clinical use of liraglutide in patients with type 1 diabetes.
https://diabetes.acponline.org/archives/2017/01/13/6.htm
13 Jan 2017
Semaglutide reduced a composite of CV events at two years in patients with type 2 diabetes and high CV risk
Semaglutide, a new once-weekly glucagon-like peptide-1 (GLP-1) analogue, reduced cardiovascular (CV) events compared to placebo, according to a manufacturer-sponsored study.
https://diabetes.acponline.org/archives/2017/02/10/7.htm
10 Feb 2017
Review: In type 2 diabetes, sodium–glucose cotransporter 2 inhibitors do not increase major CV events or mortality
The meta-analysis included 37 trials that compared canagliflozin, dapagliflozin, or empagliflozin to placebo or other active antidiabetic treatments.
https://diabetes.acponline.org/archives/2017/02/10/6.htm
10 Feb 2017
Review: Long-term dual-antiplatelet therapy (DAPT) after PCI is no better than short-term DAPT, even with diabetes
Having diabetes was associated with higher risk of a major cardiovascular event after implementation of a drug-eluting stent, according to a systematic review.
https://diabetes.acponline.org/archives/2017/03/10/6.htm
10 Mar 2017
Guideline: The USPSTF recommends low- to moderate-dose statins to prevent CVD in selected adults 40 to 75 years of age
The U.S. Preventive Services Task Force (USPSTF) issued a recommendation on use of statins for primary prevention of cardiovascular disease (CVD).
https://diabetes.acponline.org/archives/2017/04/14/6.htm
14 Apr 2017
Review: Sulfonylureas are associated with overall mortality and CV events vs other antihyperglycemics
A review looked at randomized trials that compared mortality rates among patients taking sulfonylureas versus several other classes of hypoglycemic drugs.
https://diabetes.acponline.org/archives/2017/05/12/6.htm
12 May 2017
Review: Metformin is linked to reduced mortality in type 2 diabetes with comorbid CKD and CHF
The included studies focused on metformin use in patients with chronic kidney disease (CKD), congestive heart failure (CHF), chronic liver disease (CLD), or older age.
https://diabetes.acponline.org/archives/2017/05/12/7.htm
12 May 2017
Bariatric surgery improved HbA1c at 5 y more than intensive medical care alone in obese patients with T2DM
A commentary considers the industry-funded STAMPEDE trial, in which obese patients with type 2 diabetes were randomly assigned to intensive medical therapy alone or intensive medical therapy plus Roux-en-Y gastric bypass or sleeve gastrectomy.
https://diabetes.acponline.org/archives/2017/06/09/6.htm
9 Jun 2017
Review: Dapagliflozin increases, and empagliflozin reduces, adverse renal events in type 2 diabetes
A commentary called for the findings to be confirmed with randomized controlled trials designed specifically to evaluate the effect of SGLT2 inhibitors on the kidneys.
https://diabetes.acponline.org/archives/2017/08/11/6.htm
11 Aug 2017
In type 1 diabetes, education with either insulin pumps or daily injections did not differ for HbA1c at 2 years
The results showed that when patients on multiple daily insulin injections received structured education, there was no additional benefit of switching to pump therapy for glycemic control, hypoglycemia rates, or quality of life, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2017/09/08/6.htm
8 Sep 2017